| Year |
Citation |
Score |
| 2024 |
Gausi K, Ignatius EH, De Jager V, Upton C, Kim S, McKhann A, Moran L, Wiesner L, von Groote-Bidlingmaier F, Marzinek P, Vanker N, Yvetot J, Pierre S, Rosenkranz SL, Swindells S, ... ... Dooley KE, et al. High-Dose Isoniazid Lacks EARLY Bactericidal Activity Against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized, Phase 2 Clinical Trial. American Journal of Respiratory and Critical Care Medicine. PMID 38564365 DOI: 10.1164/rccm.202311-2004OC |
0.35 |
|
| 2024 |
Dheda K, Mirzayev F, Cirillo DM, Udwadia Z, Dooley KE, Chang KC, Omar SV, Reuter A, Perumal T, Horsburgh CR, Murray M, Lange C. Multidrug-resistant tuberculosis. Nature Reviews. Disease Primers. 10: 22. PMID 38523140 DOI: 10.1038/s41572-024-00504-2 |
0.419 |
|
| 2024 |
Ngo HX, Xu AY, Velásquez GE, Zhang N, Chang VK, Kurbatova EV, Whitworth WC, Sizemore E, Bryant K, Carr W, Weiner M, Dooley KE, Engle M, Dorman SE, Nahid P, et al. Pharmacokinetic-Pharmacodynamic Evidence from a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 38462673 DOI: 10.1093/cid/ciae119 |
0.57 |
|
| 2023 |
Kengo A, Nabisere R, Gausi K, Musaazi J, Buzibye A, Omali D, Aarnoutse R, Lamorde M, Dooley KE, Sloan DJ, Denti P, Sekaggya-Wiltshire C. Dolutegravir pharmacokinetics in Ugandan patients with TB and HIV receiving standard- versus high-dose rifampicin. Antimicrobial Agents and Chemotherapy. e0043023. PMID 37850738 DOI: 10.1128/aac.00430-23 |
0.344 |
|
| 2023 |
Kengo A, Gausi K, Nabisere R, Musaazi J, Buzibye A, Omali D, Aarnoutse R, Lamorde M, Dooley KE, Sloan DJ, Sekaggya-Wiltshire C, Denti P. Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicin. Antimicrobial Agents and Chemotherapy. e0043123. PMID 37850737 DOI: 10.1128/aac.00431-23 |
0.35 |
|
| 2023 |
Geiger K, Patil A, Budhathoki C, Dooley KE, Lowensen K, Ndjeka N, Ngozo J, Farley JE. Successful Multidrug-Resistant Tuberculosis Treatment Without HIV Viral Suppression: A Missed Opportunity. Journal of Acquired Immune Deficiency Syndromes (1999). 94: 253-261. PMID 37757847 DOI: 10.1097/QAI.0000000000003268 |
0.418 |
|
| 2023 |
Naidoo A, Dooley KE. Dolutegravir once daily with rifampicin for HIV and tuberculosis. The Lancet. Hiv. PMID 37230100 DOI: 10.1016/S2352-3018(23)00115-7 |
0.362 |
|
| 2023 |
Wasmann RE, Masini T, Viney K, Verkuijl S, Brands A, Hesseling AC, McIlleron H, Denti P, Dooley KE. A model-based approach for a practical dosing strategy for the short, intensive treatment regimen for paediatric tuberculous meningitis. Frontiers in Pharmacology. 14: 1055329. PMID 37180707 DOI: 10.3389/fphar.2023.1055329 |
0.346 |
|
| 2023 |
Verboven L, Callens S, Black J, Maartens G, Dooley KE, Potgieter S, Cartuyvels R, Team S, Laukens K, Warren RM, Rie AV. A machine-learning based model for automated recommendation of individualized treatment of rifampicin-resistant tuberculosis. Research Square. PMID 36824956 DOI: 10.21203/rs.3.rs-2525765/v1 |
0.33 |
|
| 2023 |
Jarrett RT, van der Heijden Y, Shotwell MS, Chihota V, Marzinke MA, Chaisson RE, Dooley KE, Churchyard GJ. High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus. Antimicrobial Agents and Chemotherapy. e0129722. PMID 36622148 DOI: 10.1128/aac.01297-22 |
0.536 |
|
| 2022 |
Dooley KE, Hendricks B, Gupte N, Barnes G, Narunsky K, Whitelaw C, Smit T, Ignatius EH, Friedman A, Dorman SE, Dawson R. Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-containing Regimens for Drug-sensitive TB: 12-Week Results. American Journal of Respiratory and Critical Care Medicine. PMID 36455068 DOI: 10.1164/rccm.202208-1475OC |
0.441 |
|
| 2022 |
Naidoo A, Dooley KE, Naidoo K, Padayatchi N, Yende-Zuma N, Perumal R, Dorse G, Boodhram R, Osuala EC. INSTIs for the management of HIV-associated TB (INSIGHT study): a phase 2b study to evaluate the efficacy, safety and pharmacokinetics of a combination of bictegravir, emtricitabine and tenofovir alafenamide fumarate for the treatment of HIV-1 infection in patients with drug-susceptible tuberculosis on a rifampicin-based treatment regimen: a phase 2b open-label randomised controlled trial. Bmj Open. 12: e067765. PMID 36356989 DOI: 10.1136/bmjopen-2022-067765 |
0.457 |
|
| 2022 |
Jones AJ, Mathad JS, Dooley KE, Eke AC. Evidence for Implementation: Management of TB in HIV and Pregnancy. Current Hiv/Aids Reports. PMID 36308580 DOI: 10.1007/s11904-022-00641-x |
0.434 |
|
| 2022 |
Deshmukh S, Sane M, Gaikwad S, Sahasrabudhe T, Barthwal M, Lokhande R, Raskar S, Kagal A, Dharmshale S, Pradhan N, Gupte A, Alfarisi O, Gupta A, Dooley KE, Gupte N, et al. Sex differences in tuberculosis clinical presentation, drug exposure, and treatment outcomes in India. Chest. PMID 36174745 DOI: 10.1016/j.chest.2022.09.024 |
0.367 |
|
| 2022 |
Pettit AC, Phillips PP, Kurbatova E, Vernon A, Nahid P, Dawson R, Dooley KE, Sanne I, Waja Z, Mohapi L, Podany AT, Samaneka W, Savic RM, Johnson JL, Muzanyi G, et al. Rifapentine with and without moxifloxacin for pulmonary tuberculosis in people with HIV (S31/A5349). Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 36041016 DOI: 10.1093/cid/ciac707 |
0.59 |
|
| 2022 |
Sekaggya-Wiltshire C, Nabisere R, Musaazi J, Otaalo B, Aber F, Alinaitwe L, Nampala J, Najjemba L, Buzibye A, Omali D, Gausi K, Kengo A, Lamorde M, Aarnoutse R, Denti P, ... Dooley KE, et al. Decreased dolutegravir and efavirenz concentrations with preserved virological suppression in patients with TB and HIV receiving high-dose rifampicin. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 35861296 DOI: 10.1093/cid/ciac585 |
0.439 |
|
| 2022 |
Tanneau L, Karlsson MO, Rosenkranz SL, Cramer YS, Shenje J, Upton CM, Morganroth J, Diacon AH, Maartens G, Dooley KE, Svensson EM. Assessing the QTcF prolongation of bedaquiline and delamanid coadministration to predict the cardiac safety of simplified dosing regimens. Clinical Pharmacology and Therapeutics. PMID 35687528 DOI: 10.1002/cpt.2685 |
0.303 |
|
| 2022 |
Gausi K, Chirehwa M, Ignatius EH, Court R, Sun X, Moran L, Hafner R, Wiesner L, Rosenkranz SL, de Jager V, de Vries N, Harding J, Gumbo T, Swindells S, Diacon A, ... Dooley KE, et al. Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis. The Journal of Antimicrobial Chemotherapy. PMID 35678468 DOI: 10.1093/jac/dkac188 |
0.418 |
|
| 2022 |
Tanneau L, Karlsson MO, Diacon AH, Shenje J, De Los Rios J, Wiesner L, Upton CM, Dooley KE, Maartens G, Svensson EM. Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline. Clinical Pharmacokinetics. PMID 35668346 DOI: 10.1007/s40262-022-01133-2 |
0.363 |
|
| 2022 |
Kawuma AN, Wasmann RE, Dooley KE, Boffito M, Maartens G, Denti P. Population Pharmacokinetic Model and Alternative Dosing Regimens for Dolutegravir Coadministered with Rifampicin. Antimicrobial Agents and Chemotherapy. e0021522. PMID 35604212 DOI: 10.1128/aac.00215-22 |
0.335 |
|
| 2022 |
Tasneen R, Garcia A, Converse PJ, Zimmerman MD, Dartois V, Kurbatova E, Vernon AA, Carr W, Stout JE, Dooley KE, Nuermberger EL. Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models. Antimicrobial Agents and Chemotherapy. e0239821. PMID 35315690 DOI: 10.1128/aac.02398-21 |
0.357 |
|
| 2022 |
De Jager V, Gupte N, Nunes S, Barnes GL, van Wijk RC, Mostert J, Dorman SE, Abulfathi AA, Upton CM, Faraj A, Nuermberger EL, Lamichhane G, Svensson EM, Simonsson U, Diacon AH, ... Dooley KE, et al. Early Bactericidal Activity of Meropenem Plus Clavulanate (+/-Rifampin) For TB: The COMRADE Randomized, Phase 2 Trial. American Journal of Respiratory and Critical Care Medicine. PMID 35258443 DOI: 10.1164/rccm.202108-1976OC |
0.443 |
|
| 2022 |
Upton CM, Steele CI, Maartens G, Diacon AH, Wiesner L, Dooley KE. Pharmacokinetics of bedaquiline in cerebrospinal fluid (CSF) in patients with pulmonary tuberculosis (TB). The Journal of Antimicrobial Chemotherapy. PMID 35257182 DOI: 10.1093/jac/dkac067 |
0.431 |
|
| 2022 |
Naidoo A, Naidoo K, Padayatchi N, Dooley KE. Use of integrase inhibitors in HIV-associated tuberculosis in high-burden settings: implementation challenges and research gaps. The Lancet. Hiv. 9: e130-e138. PMID 35120633 DOI: 10.1016/S2352-3018(21)00324-6 |
0.481 |
|
| 2021 |
Podany AT, Pham M, Sizemore E, Martinson N, Samaneka W, Mohapi L, Badal-Faesen S, Dawson R, Johnson JL, Mayanja H, Lalloo U, Whitworth WC, Pettit A, Campbell K, Phillips P, ... ... Dooley KE, et al. Efavirenz pharmacokinetics and HIV-1 viral suppression among patients receiving TB treatment containing daily high-dose rifapentine. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 34918028 DOI: 10.1093/cid/ciab1037 |
0.619 |
|
| 2021 |
Gausi K, Ignatius EH, Sun X, Kim S, Moran L, Wiesner L, von Groote-Bidlingmaier F, Hafner R, Donahue K, Vanker N, Rosenkranz SL, Swindells S, Diacon AH, Nuermberger EL, Dooley KE, et al. A Semi-Mechanistic Model of the Bactericidal Activity of High-Dose Isoniazid Against Multi-Drug-Resistant Tuberculosis: Results from a Randomized Clinical Trial. American Journal of Respiratory and Critical Care Medicine. PMID 34403326 DOI: 10.1164/rccm.202103-0534OC |
0.384 |
|
| 2021 |
Mehtani NJ, Puryear S, Pham P, Dooley KE, Shah M. Infectious Diseases Learning Unit: Understanding Advances in the Treatment of Latent Tuberculosis Infection Among People With Human Immunodeficiency Virus. Open Forum Infectious Diseases. 8: ofab319. PMID 34395707 DOI: 10.1093/ofid/ofab319 |
0.399 |
|
| 2021 |
Mathad JS, Savic R, Britto P, Jayachandran P, Wiesner L, Montepiedra G, Norman J, Zhang N, Townley E, Chakhtoura N, Bradford S, Patil S, Popson S, Chipato T, Rouzier V, ... ... Dooley KE, et al. Pharmacokinetics and Safety of Three Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 34323955 DOI: 10.1093/cid/ciab665 |
0.382 |
|
| 2021 |
Francis J, Mngqibisa R, McIlleron H, Kendall MA, Wu X, Dooley KE, Firnhaber C, Godfrey C, Cohn SE, Denti P. A semi-mechanistic pharmacokinetic model for depot medroxyprogesterone acetate and drug-drug interactions with antiretroviral and antituberculosis treatment. Clinical Pharmacology and Therapeutics. PMID 34151439 DOI: 10.1002/cpt.2324 |
0.34 |
|
| 2021 |
Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, Engle M, Goldberg SV, Phan HTT, Hakim J, Johnson JL, Lourens M, Martinson NA, Muzanyi G, Narunsky K, et al. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. The New England Journal of Medicine. 384: 1705-1718. PMID 33951360 DOI: 10.1056/NEJMoa2033400 |
0.594 |
|
| 2021 |
Mave V, Gaikwad S, Barthwal M, Chandanwale A, Lokhande R, Kadam D, Dharmshale S, Bharadwaj R, Kagal A, Pradhan N, Deshmukh S, Atre S, Sahasrabudhe T, Meshram S, Kakrani A, ... ... Dooley KE, et al. Diabetes Mellitus and Tuberculosis Treatment Outcomes in Pune, India. Open Forum Infectious Diseases. 8: ofab097. PMID 33884278 DOI: 10.1093/ofid/ofab097 |
0.317 |
|
| 2021 |
Sturkenboom MGG, Märtson AG, Svensson EM, Sloan DJ, Dooley KE, van den Elsen SHJ, Denti P, Peloquin CA, Aarnoutse RE, Alffenaar JC. Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs. Clinical Pharmacokinetics. PMID 33674941 DOI: 10.1007/s40262-021-00997-0 |
0.433 |
|
| 2021 |
Dooley KE, Rosenkranz SL, Conradie F, Moran L, Hafner R, von Groote-Bidlingmaier F, Lama JR, Shenje J, De Los Rios J, Comins K, Morganroth J, Diacon AH, Cramer YS, Donahue K, Maartens G, et al. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial. The Lancet. Infectious Diseases. PMID 33587897 DOI: 10.1016/S1473-3099(20)30770-2 |
0.415 |
|
| 2021 |
Zhang N, Savic RM, Boeree MJ, Peloquin C, Weiner M, Heinrich N, Bliven-Sizemore E, Phillips PP, Hoelscher M, Whitworth W, Morlock G, Posey J, Stout JE, Mac Kenzie W, Aarnoutse R, ... Dooley KE, et al. Optimising pyrazinamide for the treatment of tuberculosis. The European Respiratory Journal. PMID 33542052 DOI: 10.1183/13993003.02013-2020 |
0.431 |
|
| 2020 |
Ignatius EH, Abdelwahab MT, Hendricks B, Gupte N, Narunsky K, Wiesner L, Barnes G, Dawson R, Dooley KE, Denti P. Pretomanid Pharmacokinetics in the Presence of Rifamycins: interim Results from a Randomized Trial among Patients with Tuberculosis. Antimicrobial Agents and Chemotherapy. PMID 33229425 DOI: 10.1128/AAC.01196-20 |
0.452 |
|
| 2020 |
Giridharan P, Selladurai E, Balaji S, Pramila SK, V A, Shanmugam S, Hissar S, Natrajan M, Dooley KE, Daniel BD. Drug resistant TB spine in a two year old child: A case report. The Indian Journal of Tuberculosis. 67: 374-377. PMID 32825872 DOI: 10.1016/J.Ijtb.2019.09.007 |
0.481 |
|
| 2020 |
Jacobs TG, Svensson EM, Musiime V, Rojo P, Dooley KE, McIlleron H, Aarnoutse RE, Burger DM, Turkova A, Colbers A. Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review. The Journal of Antimicrobial Chemotherapy. PMID 32785712 DOI: 10.1093/Jac/Dkaa328 |
0.525 |
|
| 2020 |
Rickman HM, Cohn S, Lala SG, Waja Z, Salazar-Austin N, Hoffmann J, Dooley KE, Hoffmann CJ, Chaisson RE, Martinson NA. Subclinical tuberculosis and adverse infant outcomes in pregnant women with HIV. International Journal of Tuberculosis and Lung Disease. 24: 681-685. PMID 32718400 DOI: 10.5588/Ijtld.19.0500 |
0.625 |
|
| 2020 |
Bigelow KM, Tasneen R, Chang YS, Dooley KE, Nuermberger EL. Preserved efficacy and reduced toxicity with intermittent linezolid dosing in combination with bedaquiline and pretomanid in a murine TB model. Antimicrobial Agents and Chemotherapy. PMID 32690647 DOI: 10.1128/Aac.01178-20 |
0.423 |
|
| 2020 |
Hibma JE, Radtke KK, Dorman SE, Jindani A, Dooley KE, Weiner M, McIlleron HM, Savic RM. Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis Infection. American Journal of Respiratory and Critical Care Medicine. PMID 32412342 DOI: 10.1164/Rccm.201912-2489Oc |
0.358 |
|
| 2020 |
Hong H, Dowdy DW, Dooley KE, Francis HW, Budhathoki C, Han HR, Farley JE. Prevalence of Pre-Existing Hearing Loss Among Patients With Drug-Resistant Tuberculosis in South Africa. American Journal of Audiology. 1-7. PMID 32320639 DOI: 10.1044/2020_Aja-19-00103 |
0.408 |
|
| 2020 |
Dooley KE, Savic R, Gupte A, Marzinke MA, Zhang N, Edward VA, Wolf L, Sebe M, Likoti M, Fyvie MJ, Shibambo I, Beattie T, Chaisson RE, Churchyard GJ. Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial. The Lancet. Hiv. PMID 32240629 DOI: 10.1016/S2352-3018(20)30032-1 |
0.598 |
|
| 2020 |
Dooley KE, Miyahara S, von Groote-Bidlingmaier F, Sun X, Hafner R, Rosenkranz SL, Ignatius EH, Nuermberger EL, Moran L, Donahue K, Swindells S, Vanker N, Diacon AH. Reply to: High-dose First-line Treatment Regimen for Recurrent Rifampicin-susceptible Tuberculosis. American Journal of Respiratory and Critical Care Medicine. PMID 32130866 DOI: 10.1164/Rccm.202002-0359Le |
0.459 |
|
| 2020 |
Eke AC, Brooks KM, Gebreyohannes RD, Sheffield JS, Dooley KE, Mirochnick M. Tenofovir alafenamide use in pregnant and lactating women living with HIV. Expert Opinion On Drug Metabolism & Toxicology. PMID 32125906 DOI: 10.1080/17425255.2020.1738384 |
0.38 |
|
| 2020 |
Nabisere R, Musaazi J, Denti P, Aber F, Lamorde M, Dooley KE, Aarnoutse R, Sloan DJ, Sekaggya-Wiltshire C. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF). Trials. 21: 181. PMID 32054536 DOI: 10.1186/S13063-020-4132-7 |
0.57 |
|
| 2020 |
Bigelow KM, Deitchman AN, Li SY, Barnes-Boyle K, Tyagi S, Soni H, Dooley KE, Savic R, Nuermberger EL. Pharmacodynamic Correlates of Linezolid Activity and Toxicity in Murine Models of Tuberculosis. The Journal of Infectious Diseases. PMID 31993638 DOI: 10.1093/Infdis/Jiaa016 |
0.422 |
|
| 2020 |
Dorman SE, Nahid P, Kurbatova EV, Goldberg SV, Bozeman L, Burman WJ, Chang KC, Chen M, Cotton M, Dooley KE, Engle M, Feng PJ, Fletcher CV, Ha P, Heilig CM, et al. High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial. Contemporary Clinical Trials. 105938. PMID 31981713 DOI: 10.1016/J.Cct.2020.105938 |
0.609 |
|
| 2020 |
Dooley KE, Miyahara S, von Groote-Bidlingmaier F, Sun X, Hafner R, Rosenkranz SL, Ignatius EH, Nuermberger EL, Moran L, Donahue K, Swindells S, Vanker N, Diacon AH. Early Bactericidal Activity of Different Isoniazid Doses for Drug Resistant TB (INHindsight): A Randomized Open-label Clinical Trial. American Journal of Respiratory and Critical Care Medicine. PMID 31945300 DOI: 10.1164/Rccm.201910-1960Oc |
0.517 |
|
| 2019 |
Abdelwahab MT, Leisegang R, Dooley KE, Mathad JS, Wiesner L, McIlleron H, Martinson N, Waja Z, Letutu M, Chaisson RE, Denti P. Population Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in South African Pregnant Women with Tuberculosis and HIV. Antimicrobial Agents and Chemotherapy. PMID 31844002 DOI: 10.1128/Aac.01978-19 |
0.607 |
|
| 2019 |
Ignatius EH, Dooley KE. New Drugs for the Treatment of Tuberculosis. Clinics in Chest Medicine. 40: 811-827. PMID 31731986 DOI: 10.1016/J.Ccm.2019.08.001 |
0.533 |
|
| 2019 |
Salazar-Austin N, Cohn S, Lala S, Waja Z, Dooley KE, Hoffmann CJ, Chaisson RE, Martinson N. Isoniazid Preventive Therapy and Pregnancy Outcomes In HIV-Infected Women in the Tshepiso Cohort. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 31631221 DOI: 10.1093/Cid/Ciz1024 |
0.531 |
|
| 2019 |
Paradkar M, Devaleenal DB, Mvalo T, Arenivas A, Thakur KT, Afrin S, Giridharan P, Selladurai E, Kinikar A, Valvi C, Gupta A, Mave V, Dooley KE. Challenges in conducting trials for pediatric tuberculous meningitis: lessons from the field. The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease. 23: 1082-1089. PMID 31627773 DOI: 10.5588/Ijtld.18.0786 |
0.328 |
|
| 2019 |
Alffenaar JC, Gumbo T, Dooley KE, Peloquin CA, McIlleron H, Zagorski A, Cirillo DM, Heysell SK, Silva DR, Migliori GB. Integrating pharmacokinetics and pharmacodynamics in operational research to End TB. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 31560376 DOI: 10.1093/Cid/Ciz942 |
0.473 |
|
| 2019 |
Mngqibisa R, Kendall MA, Dooley K, Wu X, Firnhaber C, McIlleron H, Robinson J, Cramer Y, Rosenkranz SL, Roa J, Coughlin K, Mawlana S, Badal-Faesen S, Schnabel D, Omoz-Oarhe A, et al. Pharmacokinetics and Pharmacodynamics of Depot Medroxyprogesterone Acetate (DMPA) in African women receiving treatment for HIV and TB: Potential concern for standard dosing frequency. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 31504342 DOI: 10.1093/Cid/Ciz863 |
0.495 |
|
| 2019 |
Dheda K, Gumbo T, Maartens G, Dooley KE, Murray M, Furin J, Nardell EA, Warren RM. The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. The Lancet. Respiratory Medicine. 7: 820-826. PMID 31486393 DOI: 10.1016/S2213-2600(19)30263-2 |
0.494 |
|
| 2019 |
DeMarco VP, Ordonez AA, Klunk M, Prideaux B, Wang H, Zhang Z, Tonge PJ, Dannals RF, Holt DP, Lee CKK, Weinstein EA, Dartois V, Dooley KE, Jain SK. Erratum for DeMarco et al., "Determination of [C]Rifampin Pharmacokinetics within Mycobacterium tuberculosis-Infected Mice by Using Dynamic Positron Emission Tomography Bioimaging". Antimicrobial Agents and Chemotherapy. 63. PMID 31444171 DOI: 10.1128/Aac.01368-19 |
0.303 |
|
| 2019 |
Tucker EW, Pieterse L, Zimmerman MD, Udwadia ZF, Peloquin CA, Gler MT, Ganatra S, Tornheim J, Chawla P, Caoili JC, Ritchie B, Jain SK, Dartois V, Dooley KE. Delamanid Central Nervous System Pharmacokinetics in Tuberculous Meningitis in Rabbits and Humans. Antimicrobial Agents and Chemotherapy. PMID 31383662 DOI: 10.1128/Aac.00913-19 |
0.407 |
|
| 2019 |
Sekaggya-Wiltshire C, Dooley KE. Pharmacokinetic and pharmacodynamic considerations of rifamycin antibiotics for the treatment of tuberculosis. Expert Opinion On Drug Metabolism & Toxicology. 15: 615-618. PMID 31339806 DOI: 10.1080/17425255.2019.1648432 |
0.491 |
|
| 2019 |
Radtke KK, Dooley KE, Dodd PJ, Garcia-Prats AJ, McKenna L, Hesseling AC, Savic RM. Alternative dosing guidelines to improve outcomes in childhood tuberculosis: a mathematical modelling study. The Lancet. Child & Adolescent Health. PMID 31324596 DOI: 10.1016/S2352-4642(19)30196-8 |
0.494 |
|
| 2019 |
Dooley KE, Hanna D, Mave V, Eisenach K, Savic RM. Advancing the development of new tuberculosis treatment regimens: The essential role of translational and clinical pharmacology and microbiology. Plos Medicine. 16: e1002842. PMID 31276490 DOI: 10.1371/Journal.Pmed.1002842 |
0.433 |
|
| 2019 |
Ramachandran G, Chandrasekaran P, Gaikwad S, Hemanth Kumar AK, Thiruvengadam K, Gupte N, Paradkar M, Dhanasekaran K, Sivaramakrishnan GN, Kagal A, Thomas B, Pradhan N, Kadam D, Hanna LE, Balasubramanian U, ... ... Dooley KE, et al. Sub-therapeutic rifampicin concentration is associated with unfavourable tuberculosis treatment outcomes. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 31075166 DOI: 10.1093/Cid/Ciz380 |
0.491 |
|
| 2019 |
Hong H, Dooley KE, Starbird LE, Francis HW, Farley JE. Adverse outcome pathway for aminoglycoside ototoxicity in drug-resistant tuberculosis treatment. Archives of Toxicology. PMID 30963202 DOI: 10.1007/S00204-019-02407-8 |
0.425 |
|
| 2019 |
Hong H, Dowdy DW, Dooley KE, Francis HW, Budhathoki C, Han HR, Farley JE. Aminoglycoside-Induced Hearing Loss Among Patients Being Treated for Drug-Resistant Tuberculosis in South Africa: A Prediction Model. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 30963176 DOI: 10.1093/Cid/Ciz289 |
0.451 |
|
| 2019 |
Dooley KE, Kaplan R, Mwelase N, Grinsztejn B, Ticona E, Lacerda M, Sued O, Belonosova E, Ait-Khaled M, Angelis K, Brown D, Singh R, Talarico CL, Tenorio AR, Keegan MR, et al. Dolutegravir-Based Antiretroviral Therapy for Patients Co-Infected with Tuberculosis and Hiv: A Multicenter, Noncomparative, Open-Label, Randomized Trial. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 30918967 DOI: 10.1093/Cid/Ciz256 |
0.512 |
|
| 2019 |
O'Donnell MR, Padayatchi N, Daftary A, Orrell C, Dooley KE, Rivet Amico K, Friedland G. Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection. The Lancet. Hiv. 6: e201-e204. PMID 30846058 DOI: 10.1016/S2352-3018(19)30035-9 |
0.522 |
|
| 2018 |
Cresswell FV, Te Brake L, Atherton R, Ruslami R, Dooley KE, Aarnoutse R, van Crevel R. Intensified antibiotic treatment of tuberculous meningitis. Expert Review of Clinical Pharmacology. PMID 30474434 DOI: 10.1080/17512433.2019.1552831 |
0.521 |
|
| 2018 |
Tornheim JA, Dooley KE. The Global Landscape of Tuberculosis Therapeutics. Annual Review of Medicine. PMID 30403551 DOI: 10.1146/Annurev-Med-040717-051150 |
0.533 |
|
| 2018 |
Weld ED, Dooley KE. State of the Art Review of HIV-TB coinfection in Special Populations. Clinical Pharmacology and Therapeutics. PMID 30137652 DOI: 10.1002/Cpt.1221 |
0.518 |
|
| 2018 |
Alfarisi O, Mave V, Gaikwad S, Sahasrabudhe T, Ramachandran G, Kumar H, Gupte N, Kulkarni V, Deshmukh S, Atre S, Raskar S, Lokhande R, Barthwal M, Kakrani A, Gupta A, ... ... Dooley KE, et al. The effect of diabetes mellitus on the pharmacokinetics and pharmacodynamics of tuberculosis treatment. Antimicrobial Agents and Chemotherapy. PMID 30126955 DOI: 10.1128/Aac.01383-18 |
0.458 |
|
| 2018 |
Tornheim JA, Dooley KE. Challenges of TB and HIV co-treatment: updates and insights. Current Opinion in Hiv and Aids. PMID 30080683 DOI: 10.1097/Coh.0000000000000495 |
0.536 |
|
| 2018 |
Dooley KE. Long-acting injectables for tuberculosis prophylaxis and treatment: is now the time? The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease. 22: 833-834. PMID 29991389 DOI: 10.5588/Ijtld.18.0411 |
0.419 |
|
| 2018 |
Thakur K, Das M, Dooley KE, Gupta A. The Global Neurological Burden of Tuberculosis. Seminars in Neurology. 38: 226-237. PMID 29791949 DOI: 10.1055/S-0038-1651500 |
0.465 |
|
| 2018 |
Tucker EW, Dooley KE. Preclinical tools for the evaluation of tuberculosis treatment regimens for children. The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease. 22: 7-14. PMID 29665948 DOI: 10.5588/Ijtld.17.0354 |
0.46 |
|
| 2018 |
Rifat D, Prideaux B, Savic RM, Urbanowski ME, Parsons TL, Luna B, Marzinke MA, Ordonez AA, DeMarco VP, Jain SK, Dartois V, Bishai WR, Dooley KE. Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data. Science Translational Medicine. 10. PMID 29618565 DOI: 10.1126/Scitranslmed.Aai7786 |
0.463 |
|
| 2018 |
Sekaggya-Wiltshire C, Lamorde M, Kiragga AN, Dooley KE, Kamya MR, Kambugu A, Fehr J, Manabe YC, Castelnuovo B. The utility of pharmacokinetic studies for the evaluation of exposure-response relationships for standard dose anti-tuberculosis drugs. Tuberculosis (Edinburgh, Scotland). 108: 77-82. PMID 29523331 DOI: 10.1016/J.Tube.2017.11.004 |
0.538 |
|
| 2018 |
Schalkwijk S, Ter Heine R, Colbers AC, Huitema ADR, Denti P, Dooley KE, Capparelli E, Best BM, Cressey TR, Greupink R, Russel FGM, Mirochnick M, Burger DM. A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women. Clinical Pharmacokinetics. PMID 29520730 DOI: 10.1007/S40262-018-0642-9 |
0.361 |
|
| 2018 |
Dooley KE, Kaplan R, Mwelase N, Grinsztejn B, Ticona E, Lacerda M, Sued O, Belonosova E, Ait‐Khaled M, Angelis K, Brown D, Singh R, Talarico C, Tenorio A, Keegan M, et al. Segurança E Eficácia Da Terapia Antirretroviral Baseada Em Dolutegravir, Na Semana 48, Em Adultos Coinfectados Hiv/Tb Brazilian Journal of Infectious Diseases. 22: 14-15. DOI: 10.1016/J.Bjid.2018.10.027 |
0.403 |
|
| 2018 |
Eke AC, Dooley K, Sheffield J. 858: Integrase inhibitor versus protease inhibitor (PI)-based antiretroviral therapy (ART) in late pregnancy and rapid HIV viral load reduction in ART naïve patients: Cost effectiveness analysis American Journal of Obstetrics and Gynecology. 218: S512. DOI: 10.1016/J.Ajog.2017.11.395 |
0.314 |
|
| 2017 |
Guiastrennec B, Ramachandran G, Karlsson MO, Kumar AKH, Bhavani PK, Gangadevi NP, Swaminathan S, Gupta A, Dooley KE, Savic RM. Suboptimal Anti-Tuberculosis Drug Concentrations and Outcomes in Small and HIV Coinfected Children in India: Recommendations for Dose Modifications. Clinical Pharmacology and Therapeutics. PMID 29247506 DOI: 10.1002/Cpt.987 |
0.512 |
|
| 2017 |
Mave V, Kinikar A, Kagal A, Nimkar S, Koli H, Khwaja S, Bharadwaj R, Gerona R, Wen A, Ramachandran G, Kumar H, Bacchetti P, Dooley KE, Gupte N, Gupta A, et al. Isoniazid concentrations in hair and plasma area-under-the-curve exposure among children with tuberculosis. Plos One. 12: e0189101. PMID 29216273 DOI: 10.1371/Journal.Pone.0189101 |
0.397 |
|
| 2017 |
Denti P, Garcia-Prats AJ, Draper HR, Wiesner L, Winckler J, Thee S, Dooley KE, Savic RM, McIlleron HM, Schaaf HS, Hesseling AC. Levofloxacin population pharmacokinetics in South African children treated for multidrug-resistant tuberculosis. Antimicrobial Agents and Chemotherapy. PMID 29133560 DOI: 10.1128/Aac.01521-17 |
0.411 |
|
| 2017 |
Salazar-Austin N, Hoffmann J, Cohn S, Mashabela F, Waja Z, Lala S, Hoffmann C, Dooley KE, Chaisson RE, Martinson N. Poor Obstetric and Infant Outcomes in HIV-Infected Pregnant Women with Tuberculosis in South Africa: The Tshepiso Study. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 29028970 DOI: 10.1093/Cid/Cix851 |
0.604 |
|
| 2017 |
Wilkinson RJ, Rohlwink U, Misra UK, van Crevel R, Mai NTH, Dooley KE, Caws M, Figaji A, Savic R, Solomons R, Thwaites GE. Tuberculous meningitis. Nature Reviews. Neurology. PMID 28884751 DOI: 10.1038/nrneurol.2017.120 |
0.316 |
|
| 2017 |
Alfarisi O, Alghamdi WA, Al-Shaer MH, Dooley KE, Peloquin CA. Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis? Expert Review of Clinical Pharmacology. 1-10. PMID 28803492 DOI: 10.1080/17512433.2017.1366311 |
0.552 |
|
| 2017 |
Kaushik A, Ammerman NC, Tasneen R, Story-Roller E, Dooley KE, Dorman SE, Nuermberger EL, Lamichhane G. In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis. The Journal of Antimicrobial Chemotherapy. PMID 28575382 DOI: 10.1093/Jac/Dkx152 |
0.491 |
|
| 2017 |
Bartelink IH, Zhang N, Keizer RJ, Strydom N, Converse PJ, Dooley KE, Nuermberger EL, Savic RM. New Paradigm for Translational Modeling to Predict Long-term Tuberculosis Treatment Response. Clinical and Translational Science. PMID 28561946 DOI: 10.1111/Cts.12472 |
0.418 |
|
| 2017 |
McIlleron H, Denti P, Cohn S, Mashabela F, Hoffmann JD, Shembe S, Msandiwa R, Wiesner L, Velaphi S, Lala SG, Chaisson RE, Martinson N, Dooley KE. Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants. The Journal of Antimicrobial Chemotherapy. PMID 28419277 DOI: 10.1093/Jac/Dkx112 |
0.591 |
|
| 2017 |
Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, Nardell EA, London L, Lessem E, Theron G, van Helden P, Niemann S, Merker M, Dowdy D, et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. The Lancet. Respiratory Medicine. PMID 28344011 DOI: 10.1016/S2213-2600(17)30079-6 |
0.516 |
|
| 2017 |
Weld ED, Garcia-Prats AJ, Furin JJ, Bailey TC, Hesseling AC, Dooley KE. The time has come: sparing injectables in paediatric MDR-TB. The Lancet. Respiratory Medicine. PMID 28344008 DOI: 10.1016/S2213-2600(17)30078-4 |
0.445 |
|
| 2017 |
Alsultan A, Savic R, Dooley KE, Weiner M, Whitworth W, Mac Kenzie WR, Peloquin CA. Population Pharmacokinetics of Pyrazinamide in Patients with Tuberculosis. Antimicrobial Agents and Chemotherapy. PMID 28289033 DOI: 10.1128/Aac.02625-16 |
0.428 |
|
| 2017 |
Tornheim JA, Dooley KE. Tuberculosis Associated with HIV Infection. Microbiology Spectrum. 5. PMID 28233512 DOI: 10.1128/Microbiolspec.Tnmi7-0028-2016 |
0.503 |
|
| 2017 |
Savic RM, Weiner M, Mac Kenzie WR, Engle M, Whitworth WC, Johnson JL, Nsubuga P, Nahid P, Nguyen NV, Peloquin CA, Dooley KE, Dorman SE. Defining the Optimal Dose of Rifapentine for Pulmonary Tuberculosis: Exposure-Response Relations From Two Phase 2 Clinical Trials. Clinical Pharmacology and Therapeutics. PMID 28124478 DOI: 10.1002/Cpt.634 |
0.428 |
|
| 2017 |
Kendall EA, Shrestha S, Cohen T, Nuermberger E, Dooley KE, Gonzalez-Angulo L, Churchyard GJ, Nahid P, Rich ML, Bansbach C, Forissier T, Lienhardt C, Dowdy DW. Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model. Plos Medicine. 14: e1002202. PMID 28045934 DOI: 10.1371/Journal.Pmed.1002202 |
0.534 |
|
| 2016 |
McAnaw SE, Hesseling AC, Seddon JA, Dooley KE, Garcia-Prats AJ, Kim S, Jenkins HE, Schaaf HS, Sterling TR, Horsburgh CR. Pediatric Multidrug Resistant Tuberculosis Clinical Trials: Challenges and Opportunities. International Journal of Infectious Diseases : Ijid : Official Publication of the International Society For Infectious Diseases. PMID 27955992 DOI: 10.1016/J.Ijid.2016.11.423 |
0.454 |
|
| 2016 |
Conde MB, Mello FC, Duarte RS, Cavalcante SC, Rolla V, Dalcolmo M, Loredo C, Durovni B, Armstrong DT, Efron A, Barnes GL, Marzinke MA, Savic RM, Dooley KE, Cohn S, et al. A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis. Plos One. 11: e0154778. PMID 27159505 DOI: 10.1371/Journal.Pone.0154778 |
0.634 |
|
| 2016 |
Mave V, Chandanwale A, Kinikar A, Khadse S, Kagal A, Gupte N, Suryavanshi N, Nimkar S, Koli H, Khwaja S, Bharadwaj R, Joshi S, Horng H, Benet LZ, Ramachandran G, ... Dooley KE, et al. Isoniazid hair concentrations in children with tuberculosis: a proof of concept study. The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease. 20: 844-847. PMID 27155191 DOI: 10.5588/Ijtld.15.0882 |
0.454 |
|
| 2016 |
Furin J, Alirol E, Allen E, Fielding K, Merle C, Abubakar I, Andersen J, Davies G, Dheda K, Diacon A, Dooley KE, Dravnice G, Eisenach K, Everitt D, Ferstenberg D, et al. Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults. The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease. 20: 290-294. PMID 27046707 DOI: 10.5588/Ijtld.15.0490 |
0.49 |
|
| 2016 |
Phillips PP, Dooley KE, Gillespie SH, Heinrich N, Stout JE, Nahid P, Diacon AH, Aarnoutse RE, Kibiki GS, Boeree MJ, Hoelscher M. A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP). Bmc Medicine. 14: 51. PMID 27004726 DOI: 10.1186/S12916-016-0597-3 |
0.355 |
|
| 2016 |
Dooley KE, Phillips PP, Nahid P, Hoelscher M. Challenges in the clinical assessment of novel tuberculosis drugs. Advanced Drug Delivery Reviews. PMID 26827911 DOI: 10.1016/J.Addr.2016.01.014 |
0.535 |
|
| 2016 |
Furin J, Alirol E, Allen E, Fielding K, Merle C, Abubakar I, Andersen J, Davies G, Dheda K, Diacon A, Dooley KE, Dravnice G, Eisenach K, Everitt D, Ferstenberg D, et al. Drug-resistant tuberculosis clinical trials: Proposed core research definitions in adults International Journal of Tuberculosis and Lung Disease. 20: 290-294. DOI: 10.5588/ijtld.15.0490 |
0.314 |
|
| 2015 |
Gupta A, Mathad JS, Abdel-Rahman SM, Albano JD, Botgros R, Brown V, Browning RS, Dawson L, Dooley KE, Gnanashanmugam D, Grinsztejn B, Hernandez-Diaz S, Jean-Philippe P, Kim P, Lyerly AD, et al. Towards Earlier Inclusion of Pregnant and Postpartum Women in TB Drug Trials: Consensus Statements from an International Expert Panel. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 26658057 DOI: 10.1093/Cid/Civ991 |
0.523 |
|
| 2015 |
Denti P, Martinson N, Cohn S, Mashabela F, Hoffmann J, Msandiwa R, Castel S, Wiesner L, Chaisson RE, McIlleron H, Dooley KE. Population pharmacokinetics of rifampicin in pregnant women with tuberculosis and HIV co-infection in Soweto, South Africa. Antimicrobial Agents and Chemotherapy. PMID 26643345 DOI: 10.1128/Aac.02051-15 |
0.594 |
|
| 2015 |
Svensson EM, Acharya C, Clauson B, Dooley KE, Karlsson MO. Pharmacokinetic Interactions for Drugs with a Long Half-Life-Evidence for the Need of Model-Based Analysis. The Aaps Journal. PMID 26463060 DOI: 10.1208/S12248-015-9829-2 |
0.343 |
|
| 2015 |
Hoffmann CJ, Cohn S, Mashabela F, Hoffmann JD, McIlleron H, Denti P, Haas D, Dooley KE, Martinson NA, Chaisson RE. Treatment failure, drug resistance, and CD4 T-cell count decline among postpartum women on antiretroviral therapy in South Africa. Journal of Acquired Immune Deficiency Syndromes (1999). PMID 26334739 DOI: 10.1097/Qai.0000000000000811 |
0.51 |
|
| 2015 |
Savic RM, Ruslami R, Hibma JE, Hesseling A, Ramachandran G, Ganiem AR, Swaminathan S, McIlleron H, Gupta A, Thakur K, van Crevel R, Aarnoutse R, Dooley KE. Pediatric tuberculous meningitis: model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children. Clinical Pharmacology and Therapeutics. PMID 26260983 DOI: 10.1002/Cpt.202 |
0.392 |
|
| 2015 |
Srikrishna G, Gupta S, Dooley KE, Bishai WR. Can the addition of verapamil to bedaquiline-containing regimens improve tuberculosis treatment outcomes? A novel approach to optimizing TB treatment. Future Microbiology. 10: 1257-60. PMID 26226503 DOI: 10.2217/Fmb.15.56 |
0.463 |
|
| 2015 |
Garcia-Prats AJ, Draper HR, Thee S, Dooley KE, McIlleron HM, Seddon JA, Wiesner L, Castel S, Schaaf HS, Hesseling AC. Pharmacokinetics and Safety of Ofloxacin in Children with Drug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy. 59: 6073-9. PMID 26195507 DOI: 10.1128/Aac.01404-15 |
0.462 |
|
| 2015 |
DeMarco VP, Ordonez AA, Klunk M, Prideaux B, Wang H, Zhuo Z, Tonge PJ, Dannals RF, Holt DP, Lee CK, Weinstein EA, Dartois V, Dooley KE, Jain SK. Determination of 11C-Rifampin Pharmacokinetics within Mycobacterium tuberculosis-Infected Mice Using Dynamic Positron Emission Tomography Bioimaging. Antimicrobial Agents and Chemotherapy. PMID 26169396 DOI: 10.1128/Aac.01146-15 |
0.413 |
|
| 2015 |
Dooley KE, Savic RM, Park JG, Cramer Y, Hafner R, Hogg E, Janik J, Marzinke MA, Patterson K, Benson CA, Hovind L, Dorman SE, Haas DW. Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers. Antimicrobial Agents and Chemotherapy. 59: 3399-405. PMID 25824215 DOI: 10.1128/Aac.05128-14 |
0.432 |
|
| 2015 |
Svensson EM, Murray S, Karlsson MO, Dooley KE. Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug. The Journal of Antimicrobial Chemotherapy. 70: 1106-14. PMID 25535219 DOI: 10.1093/Jac/Dku504 |
0.504 |
|
| 2015 |
Dorman SE, Savic RM, Goldberg S, Stout JE, Schluger N, Muzanyi G, Johnson JL, Nahid P, Hecker EJ, Heilig CM, Bozeman L, Feng PJ, Moro RN, MacKenzie W, Dooley KE, et al. Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. American Journal of Respiratory and Critical Care Medicine. 191: 333-43. PMID 25489785 DOI: 10.1164/Rccm.201410-1843Oc |
0.473 |
|
| 2015 |
Dooley KE, Denti P, Martinson N, Cohn S, Mashabela F, Hoffmann J, Haas DW, Hull J, Msandiwa R, Castel S, Wiesner L, Chaisson RE, McIlleron H. Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection. The Journal of Infectious Diseases. 211: 197-205. PMID 25081933 DOI: 10.1093/Infdis/Jiu429 |
0.601 |
|
| 2014 |
Sheffield JS, Siegel D, Mirochnick M, Heine RP, Nguyen C, Bergman KL, Savic RM, Long J, Dooley KE, Nesin M. Designing drug trials: considerations for pregnant women. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 59: S437-44. PMID 25425722 DOI: 10.1093/Cid/Ciu709 |
0.367 |
|
| 2014 |
Svensson EM, Dooley KE, Karlsson MO. Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection. Antimicrobial Agents and Chemotherapy. 58: 6406-12. PMID 25114140 DOI: 10.1128/Aac.03246-14 |
0.498 |
|
| 2014 |
Dooley KE, Luetkemeyer AF, Park JG, Allen R, Cramer Y, Murray S, Sutherland D, Aweeka F, Koletar SL, Marzan F, Bao J, Savic R, Haas DW. Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin. Antimicrobial Agents and Chemotherapy. 58: 5245-52. PMID 24957823 DOI: 10.1128/Aac.03332-14 |
0.43 |
|
| 2014 |
Cherkaoui I, Sabouni R, Ghali I, Kizub D, Billioux AC, Bennani K, Bourkadi JE, Benmamoun A, Lahlou O, Aouad RE, Dooley KE. Treatment default amongst patients with tuberculosis in urban Morocco: predicting and explaining default and post-default sputum smear and drug susceptibility results. Plos One. 9: e93574. PMID 24699682 DOI: 10.1371/Journal.Pone.0093574 |
0.508 |
|
| 2014 |
Savic RM, Lu Y, Bliven-Sizemore E, Weiner M, Nuermberger E, Burman W, Dorman SE, Dooley KE. Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability. Antimicrobial Agents and Chemotherapy. 58: 3035-42. PMID 24614383 DOI: 10.1128/Aac.01918-13 |
0.396 |
|
| 2013 |
Dooley KE, Nuermberger EL, Diacon AH. Pipeline of drugs for related diseases: tuberculosis. Current Opinion in Hiv and Aids. 8: 579-85. PMID 24100880 DOI: 10.1097/Coh.0000000000000009 |
0.55 |
|
| 2013 |
Williamson B, Dooley KE, Zhang Y, Back DJ, Owen A. Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine. Antimicrobial Agents and Chemotherapy. 57: 6366-9. PMID 24060875 DOI: 10.1128/Aac.01124-13 |
0.321 |
|
| 2013 |
Svensson EM, Aweeka F, Park JG, Marzan F, Dooley KE, Karlsson MO. Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis. Antimicrobial Agents and Chemotherapy. 57: 2780-7. PMID 23571542 DOI: 10.1128/Aac.00191-13 |
0.488 |
|
| 2013 |
Dooley KE, Sayre P, Borland J, Purdy E, Chen S, Song I, Peppercorn A, Everts S, Piscitelli S, Flexner C. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. Journal of Acquired Immune Deficiency Syndromes (1999). 62: 21-7. PMID 23075918 DOI: 10.1097/Qai.0B013E318276Cda9 |
0.496 |
|
| 2013 |
Dooley KE, Mitnick C, Degroote MA, Obuku E, Hamilton CD, Makhene M, Shah S, Brust JC, Durakovic N, Nuermberger E. Reply to Seddon, Schaaf, and Hesseling. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 56: 168-9. PMID 22990846 DOI: 10.1093/Cid/Cis820 |
0.432 |
|
| 2013 |
Dooley KE, Obuku EA, Durakovic N, Belitsky V, Mitnick C, Nuermberger EL. World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential? The Journal of Infectious Diseases. 207: 1352-8. PMID 22807518 DOI: 10.1093/Infdis/Jis460 |
0.47 |
|
| 2012 |
Dooley KE, Kim PS, Williams SD, Hafner R. TB and HIV Therapeutics: Pharmacology Research Priorities. Aids Research and Treatment. 2012: 874083. PMID 22829999 DOI: 10.1155/2012/874083 |
0.556 |
|
| 2012 |
Kizub D, Ghali I, Sabouni R, Bourkadi JE, Bennani K, El Aouad R, Dooley KE. Qualitative study of perceived causes of tuberculosis treatment default among health care workers in Morocco. The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease. 16: 1214-20. PMID 22793783 DOI: 10.5588/Ijtld.11.0626 |
0.457 |
|
| 2012 |
Dooley KE, Mitnick CD, Ann DeGroote M, Obuku E, Belitsky V, Hamilton CD, Makhene M, Shah S, Brust JC, Durakovic N, Nuermberger E. Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 55: 572-81. PMID 22615332 DOI: 10.1093/Cid/Cis487 |
0.502 |
|
| 2012 |
Dooley KE, Bliven-Sizemore EE, Weiner M, Lu Y, Nuermberger EL, Hubbard WC, Fuchs EJ, Melia MT, Burman WJ, Dorman SE. Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers. Clinical Pharmacology and Therapeutics. 91: 881-8. PMID 22472995 DOI: 10.1038/Clpt.2011.323 |
0.336 |
|
| 2012 |
Dooley KE, Park JG, Swindells S, Allen R, Haas DW, Cramer Y, Aweeka F, Wiggins I, Gupta A, Lizak P, Qasba S, van Heeswijk R, Flexner C. Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267. Journal of Acquired Immune Deficiency Syndromes (1999). 59: 455-62. PMID 22126739 DOI: 10.1097/Qai.0B013E3182410503 |
0.471 |
|
| 2011 |
Dooley KE, Lahlou O, Ghali I, Knudsen J, Elmessaoudi MD, Cherkaoui I, El Aouad R. Risk factors for tuberculosis treatment failure, default, or relapse and outcomes of retreatment in Morocco. Bmc Public Health. 11: 140. PMID 21356062 DOI: 10.1186/1471-2458-11-140 |
0.476 |
|
| 2011 |
Almeida D, Converse PJ, Ahmad Z, Dooley KE, Nuermberger EL, Grosset JH. Activities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in mice. Plos Neglected Tropical Diseases. 5: e933. PMID 21245920 DOI: 10.1371/Journal.Pntd.0000933 |
0.351 |
|
| 2011 |
Burman W, Dooley KE, Nuermberger EL. The rifamycins: Renewed interest in an old drug class Progress in Respiratory Research. 40: 18-24. DOI: 10.1159/000324212 |
0.414 |
|
| 2010 |
Matteelli A, Carvalho AC, Dooley KE, Kritski A. TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiology. 5: 849-58. PMID 20521931 DOI: 10.2217/Fmb.10.50 |
0.567 |
|
| 2009 |
Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. The Lancet. Infectious Diseases. 9: 737-46. PMID 19926034 DOI: 10.1016/S1473-3099(09)70282-8 |
0.537 |
|
| 2009 |
Dooley KE, Tang T, Golub JE, Dorman SE, Cronin W. Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis. The American Journal of Tropical Medicine and Hygiene. 80: 634-9. PMID 19346391 DOI: 10.4269/Ajtmh.2009.80.634 |
0.357 |
|
| 2009 |
Ribeiro S, Dooley K, Hackman J, Loredo C, Efron A, Chaisson RE, Conde MB, Boechat N, Dorman SE. T-SPOT.TB responses during treatment of pulmonary tuberculosis. Bmc Infectious Diseases. 9: 23. PMID 19250549 DOI: 10.1186/1471-2334-9-23 |
0.578 |
|
| 2008 |
Dooley K, Flexner C, Hackman J, Peloquin CA, Nuermberger E, Chaisson RE, Dorman SE. Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrobial Agents and Chemotherapy. 52: 4037-42. PMID 18765687 DOI: 10.1128/Aac.00554-08 |
0.525 |
|
| 2008 |
Dooley KE, Flexner C, Andrade AS. Drug interactions involving combination antiretroviral therapy and other anti-infective agents: repercussions for resource-limited countries. The Journal of Infectious Diseases. 198: 948-61. PMID 18713054 DOI: 10.1086/591459 |
0.328 |
|
| 2005 |
Dooley KE, Sterling TR. Treatment of latent tuberculosis infection: challenges and prospects. Clinics in Chest Medicine. 26: 313-26, vii. PMID 15837113 DOI: 10.1016/j.ccm.2005.02.003 |
0.356 |
|
| 2003 |
Ginsburg AS, Hooper N, Parrish N, Dooley KE, Dorman SE, Booth J, Diener-West M, Merz WG, Bishai WR, Sterling TR. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 37: 1448-52. PMID 14614666 DOI: 10.1086/379328 |
0.456 |
|
| 2002 |
Abiad H, Dooley KE, Golub J, Sterling TR. Does the use of fluoroquinolones for the empiric treatment of pneumonia delay initiation of treatment of tuberculosis? [1] (multiple letters) Clinical Infectious Diseases. 35: 1572-1573. PMID 12471582 |
0.304 |
|
| 2002 |
Dooley KE, Golub J, Goes FS, Merz WG, Sterling TR. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 34: 1607-12. PMID 12032896 DOI: 10.1086/340618 |
0.433 |
|
| Show low-probability matches. |